Analysis of risk factors of thrombocytopenia toxicityduring concurrent chemoradiation of gastric cancer
10.3760/cma.j.cn113030-20210802-00283
- VernacularTitle:胃癌同期放化疗所致血小板减少危险因素分析
- Author:
Li ZHANG
1
;
Yujing ZHANG
;
Jijin WANG
;
Li ZHANG
;
Xiaojun CAI
;
Ying SONG
Author Information
1. 湖北医药学院附属十堰市人民医院肿瘤科Ⅱ病区，十堰 442000
- Keywords:
Gastric neoplasm/chemoradiotherapy;
Thrombopenia;
Factor analysis
- From:
Chinese Journal of Radiation Oncology
2022;31(2):160-164
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the related risk factors of thrombocytopenia grade 2+ G2(+ )] in patients with gastric cancer during chemoradiotherapy.Methods:The pre-treatmentclinical data, hematologic parameters, and the correlation between dose distribution of vertebrae andTPG2(+ ) in non-metastaticgastric adenocarcinoma patients receiving concurrent chemoradiation in Sun Yat-sen University Cancer Center were retrospectively analyzed.Results:A total of 58 patients were included, including 23 cases (40%) in theTPG2(+ ) group and 35(60%) in the TPG2(-) group. There was no statistical difference in baseline clinical data between two groups (all P>0.05). Univariate Logistic regression analysis showed that several baseline parameters including platelet count (PLT), basophil count (BA), lactate dehydrogenase (LDH) and length of CTV (LCTV), the number of vertebrae (VBN), vertebral body volume (VBV), D max, D mean, V 5Gy, V 10Gy, V 20Gy, V 30Gy and V 40Gywere correlated with TPG2(+ )(all P<0.05). However, the multivariate Logistic regressionanalysisshowed that low PLT ( P=0.048), high LDH ( P=0.028), increased LCTV ( P=0.013), high V 20Gy/VBN ( P=0.030) were associated with the risk of TPG2(+ ). Conclusion:In gastric adenocarcinoma patients treated with chemoradiotherapy, correction of PLT reduction before treatment, avoidinglonger CTV and controlled V 20Gy correction for vertebral number may reduce significant thrombocytopenia induced by chemoradiotherapy.
